Upadacitinib demonstrated significant clinical and endoscopic remission in Crohn's disease patients, including those with prior advanced therapy exposure, without new safety signals. The study ...

A total of 209 patients received upadacitinib at a dose of 15 mg, 107 received upadacitinib at a dose of 7.5 mg, and 112 received placebo; 70% of the patients had new-onset giant-cell arteritis ...

The study was an open-label extension of two phase 3 studies. Response to upadacitinib was maintained, with responses of “similar magnitude” after switching from placebo. Upadacitinib sustains ...